title: [Transmission of human immunodeficiency virus to the fetus during pregnancy].
abstract: Estimates of the rate of human immunodeficiency virus vertical transmission range from 15% to 40%, and the rate is lower in European and American studies than in African studies. There appears to be a relationship between maternal factors, mode of delivery and mother-to-child transmission. The risk factors or markers associated with increased vertical transmission are analyzed in this review. The use of zidovudine, administered to HIV-infected women during pregnancy and labour, and to the offspring for 6 weeks reduce the mother-to-infant transmission rate from 25% to 8%. Other strategies to alter transmission of HIV, including the use of combinaison of anti-retroviral drugs, immunoprophylaxis against HIV or obstetric interventions needs to be evaluated.
authors: Service de Gynecologie-Obstetrique B, Hopital de la Conception, Marseille.
authors: C
authors: C
authors: d'Ercole
authors: L
authors: L
authors: Cravello
authors: D
authors: D
authors: Sperandeo
authors: F
authors: F
authors: Bretelle
authors: L
authors: L
authors: Piechon
authors: L
authors: L
authors: Boubli
authors: B
authors: B
authors: Blanc
mesh_terms: D000963:Antimetabolites / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000517:prevention & control / Q000628:therapy / Q000635:transmission*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control / Q000628:therapy / Q000821:virology*; D011296:Prenatal Diagnosis; D011379:Prognosis; D012307:Risk Factors; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D000963:Antimetabolites; D015215:Zidovudine
vernacular_title: Transmission du virus de l'immunodéficience humaine à l'enfant pendant la grossesse.